Eddingpharm (Cayman) Inc., a Shanghai firm that seeks to in-license and then market Western drugs to hospitals in China, has closed a $24 million Series B financing. The company said it would use the new capital to in-license additional drugs, co-develop prescription drugs for sale in China, and seek M&A opportunities. More details....